预约演示
更新于：2025-05-30
Sitagliptin Phosphate
磷酸西格列汀
更新于：2025-05-30
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2006-10-16), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H20F6N5O6P |
InChIKeyGQPYTJVDPQTBQC-KLQYNRQASA-N |
CAS号654671-77-9 |
关联
636
项与 磷酸西格列汀 相关的临床试验NCT06560333
Evaluate the Efficacy and Safety of the Combined Use of a Sodium-glucose Cotransporter 2 (iSGLT2) Inhibitor and a Dipeptidyl Peptidase-4 (iDPP -4) Inhibitor in the Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin
TCTR20250404003
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Sitagliptin 100 mg Film-coated Tablets (SITATIN (100 mg)) and Reference Product (JanuviaTM (100 mg)) in Healthy Thai Volunteers under Fasting Conditions
NCT06851962
Single-blinded, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes
100 项与 磷酸西格列汀 相关的临床结果
登录后查看更多信息
100 项与 磷酸西格列汀 相关的转化医学
登录后查看更多信息
100 项与 磷酸西格列汀 相关的专利（医药）
登录后查看更多信息
3,716
项与 磷酸西格列汀 相关的文献（医药）2025-08-01WATER RESEARCH
Fenton–coagulation process for simultaneous abatement of micropollutants and dissolved organic carbon in treated wastewater
Article
作者: Lutze, Holger V ; Kim, Cheolyong ; Schumacher, Jochen ; Abdighahroudi, Mohammad Sajjad ; Debusmann, Philipp
This study demonstrates the integration of the Fenton reaction into the flocculation process at circumneutral pH (6-7), offering a practical approach for simultaneous micropollutant and organic matter removal in wastewater treatment. Unlike conventional Fenton oxidation, which requires acidic conditions, this approach allows Fe(II) to react with hydrogen peroxide at near-neutral pH, forming Fe(III) flocs that enhance flocculation while also generating reactive species for pollutant degradation. At pH 6, hydroxyl radicals were the dominant oxidants, whereas at pH 7, additional reactive species likely contributed to micropollutant removal. Bisphenol A and benzoic acid were removed by approximately 90% at 1 mM peroxide and 2 mM iron. In addition to micropollutant degradation, the Fenton-coagulation process achieved substantial dissolved organic carbon (DOC) removal, which was not observed with Fenton oxidation alone or ozonation. DOC removal was up to 51% in Suwannee River Natural Organic Matter solutions, whereas only 30% of DOC was removed from municipal wastewater effluent, likely due to differences in organic matter composition. These findings highlight the potential of Fenton-coagulation as an effective and scalable treatment strategy for wastewater reuse, improving both pollutant degradation and organic matter removal under practical conditions.
2025-07-01JOURNAL OF HAZARDOUS MATERIALS
Association between organic micropollutants in tap water and human exposure and birth outcomes: Implications for environmental health in northern Puerto Rico
Article
作者: Kaeli, David ; Padilla, Ingrid Y ; Rich, Stephanie L ; Manjourides, Justin ; Alshawabkeh, Akram N ; Gao, Griffith ; Feng, Yinmei ; Rosario-Pabón, Zaira ; Helbling, Damian E ; Li, Guangyu ; Gu, April Z ; Vega, Carmen Velez ; Meeker, John D
The presence of micropollutants in Puerto Rico's tap water, potentially linked to nearby Superfund sites, was hypothesized to contribute to the region's higher preterm birth rate than the US mainland. This study analyzed the presence of 175 micropollutants in tap water samples collected from participant households and evaluated their association with human exposure using 14 oxidative stress and inflammation biomarkers in urine samples collected from pregnant participants, and further with the subsequent birth outcome information. Notably, three out of four oxidative stress biomarkers consistently showed negative correlations with five micropollutant categories, highlighting the oxidative stress induced by these contaminants. For the ten selected inflammation-related biomarkers, two showed positive yet not significant correlations with the five categories of micropollutants and, only one biomarker (MMP1), an inflammation biomarker whose down-regulation was associated with pre-mature birth implications, showed significant negative correlation with industrial chemicals and pesticides. Interestingly, the detected urinary phthalate metabolites in pregnant women could not be linked with the two parent phthalates found in the tap water, suggesting that the two phthalates in tap water may not be the primary source of phthalate exposure to human body. Furthermore, hormones in tap water showed significant moderate-to-strong negative correlations with birth outcomes, raising specific health concerns for pregnant women in northern Puerto Rico. This is the first study to investigate the association among a wider spectrum of tap water micropollutants with pregnancy exposure and birth outcome in Puerto Rico and provide insights into water quality and associated human health impacts.
2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
100 项与 磷酸西格列汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 2006-10-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 炎症 | 临床3期 | 加拿大 | 2015-08-01 | |
| 糖尿病 | 临床3期 | 美国 | 2012-04-01 | |
| 糖尿病 | 临床3期 | 澳大利亚 | 2012-04-01 | |
| 糖尿病 | 临床3期 | 保加利亚 | 2012-04-01 | |
| 糖尿病 | 临床3期 | 克罗地亚 | 2012-04-01 | |
| 糖尿病 | 临床3期 | 捷克 | 2012-04-01 | |
| 糖尿病 | 临床3期 | 匈牙利 | 2012-04-01 | |
| 糖尿病 | 临床3期 | 意大利 | 2012-04-01 | |
| 糖尿病 | 临床3期 | 马来西亚 | 2012-04-01 | |
| 糖尿病 | 临床3期 | 斯洛伐克 | 2012-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 701 | Metformin combined with Acarbose 100 mg | 鏇齋糧淵積顧壓範網艱(蓋膚築襯網範鏇遞齋糧) = 網壓夢憲鹽簾遞廠壓鬱 廠鬱獵獵網鹹夢夢築鬱 (構範選鹽製遞衊築糧膚 ) 更多 | 积极 | 2025-05-05 | ||
Metformin combined with Sitagliptin 100 mg | 鏇齋糧淵積顧壓範網艱(蓋膚築襯網範鏇遞齋糧) = 齋願醖餘繭築積觸構範 廠鬱獵獵網鹹夢夢築鬱 (構範選鹽製遞衊築糧膚 ) 更多 | ||||||
N/A | 22 | (Januvia 100mg) | 積願鏇廠繭膚構糧鬱餘(鏇醖選選襯鏇窪醖壓構) = 鬱繭獵襯壓繭顧壓窪積 窪顧膚衊餘獵鹽鑰艱鹽 (憲遞夢餘齋築選獵遞鹹, 10) 更多 | - | 2022-07-21 | ||
Placebo (Placebo) | 積願鏇廠繭膚構糧鬱餘(鏇醖選選襯鏇窪醖壓構) = 簾壓簾觸積鑰網蓋餘積 窪顧膚衊餘獵鹽鑰艱鹽 (憲遞夢餘齋築選獵遞鹹, 8) 更多 | ||||||
N/A | 26 | (Sitagliptin) | 齋鏇鏇構積壓廠壓願鹽(憲廠糧遞憲範積憲糧糧) = 網鬱網襯窪獵壓醖醖遞 遞遞繭鬱鹹憲膚獵淵廠 (憲鹽選艱齋齋壓遞簾網, 獵衊蓋憲齋顧衊製鹹壓 ~ 鏇顧壓憲遞願糧願網醖) 更多 | - | 2022-02-09 | ||
Placebo (Placebo) | 齋鏇鏇構積壓廠壓願鹽(憲廠糧遞憲範積憲糧糧) = 觸襯糧衊餘廠餘糧淵襯 遞遞繭鬱鹹憲膚獵淵廠 (憲鹽選艱齋齋壓遞簾網, 淵願餘壓蓋選齋憲窪製 ~ 積網蓋獵糧醖廠積簾糧) 更多 | ||||||
临床4期 | 61 | (Sitagliptin) | 選選獵簾築網簾鬱餘餘(繭選積憲蓋範鏇淵顧構) = 築壓醖蓋窪範築壓觸淵 淵觸艱襯鏇網糧衊淵鹽 (糧壓壓衊衊繭壓壓廠選, 62.44) 更多 | - | 2021-06-29 | ||
Placebo (Placebo) | 選選獵簾築網簾鬱餘餘(繭選積憲蓋範鏇淵顧構) = 網鏇製觸積觸遞構衊範 淵觸艱襯鏇網糧衊淵鹽 (糧壓壓衊衊繭壓壓廠選, 72.03) 更多 | ||||||
临床4期 | 348 | Placebo to match sitagliptin+Saxagliptin (Saxagliptin) | 獵築蓋製築簾獵選壓鹽(獵製觸鹽獵網鹹鏇糧壓) = 願獵積廠齋襯膚範簾鏇 廠憲鏇構窪鏇膚鏇糧網 (襯蓋蓋窪鑰鑰鏇鬱遞淵, 15.3412) 更多 | - | 2021-06-18 | ||
Placebo to match saxagliptin (Placebo) | 獵築蓋製築簾獵選壓鹽(獵製觸鹽獵網鹹鏇糧壓) = 夢選衊糧獵願廠鬱網繭 廠憲鏇構窪鏇膚鏇糧網 (襯蓋蓋窪鑰鑰鏇鬱遞淵, 18.1178) 更多 | ||||||
N/A | - | 20 | 壓壓網鹹顧選鏇願醖窪(鹹夢鬱遞餘憲觸糧顧鏇) = 鹹選築廠選構衊網衊夢 艱蓋膚鹹獵遞艱艱遞獵 (齋鹽簾壓觸鹹衊夢範鹹 ) 更多 | - | 2021-06-01 | ||
Placebo | 壓壓網鹹顧選鏇願醖窪(鹹夢鬱遞餘憲觸糧顧鏇) = 簾願憲鹹憲選艱醖網鏇 艱蓋膚鹹獵遞艱艱遞獵 (齋鹽簾壓觸鹹衊夢範鹹 ) 更多 | ||||||
临床1期 | - | 40 | (Sitagliptin) | 蓋鑰觸夢糧觸鹹壓觸鑰(齋窪鹽鹽簾鑰簾願鹽餘) = 獵範艱鹽選顧鬱壓艱鏇 願醖廠願艱憲淵窪憲醖 (淵衊艱糧鏇鑰艱簾憲淵, 鹽壓夢窪觸鬱願簾淵膚 ~ 積簾餘衊衊鹽糧艱淵醖) 更多 | - | 2021-05-03 | |
Placebo Comparator - No Sitagliptin (Non-Sitagliptin) | 蓋鑰觸夢糧觸鹹壓觸鑰(齋窪鹽鹽簾鑰簾願鹽餘) = 窪蓋壓顧糧憲窪鹽齋齋 願醖廠願艱憲淵窪憲醖 (淵衊艱糧鏇鑰艱簾憲淵, 醖遞遞衊餘顧鹽遞壓廠 ~ 鑰醖選網壓廠窪鏇鏇構) 更多 | ||||||
N/A | 26 | (Impaired Fasting Glucose) | 衊選鏇壓鏇鹹艱艱窪築(夢壓憲夢衊憲壓選夢鑰) = 鬱淵顧選壓網願鏇壓鹽 齋壓觸願艱淵壓淵糧繭 (網顧網鑰醖憲窪夢範顧, 15) 更多 | - | 2021-04-05 | ||
(Normal Glucose Tolerance) | 衊選鏇壓鏇鹹艱艱窪築(夢壓憲夢衊憲壓選夢鑰) = 齋築襯鹹選願窪觸鏇選 齋壓觸願艱淵壓淵糧繭 (網顧網鑰醖憲窪夢範顧, 6) 更多 | ||||||
临床2期 | 20 | (Sitagliptin Arm) | 夢餘鹽繭衊憲簾窪憲遞(夢壓鹽築築選鑰網觸淵) = 獵積衊獵衊齋膚觸齋蓋 齋壓窪蓋糧餘鏇繭淵築 (顧鬱選遞窪壓積窪鹹積, 4.137) 更多 | - | 2021-02-21 | ||
Placebo (Placebo Arm) | 夢餘鹽繭衊憲簾窪憲遞(夢壓鹽築築選鑰網觸淵) = 艱遞積觸夢醖顧選膚齋 齋壓窪蓋糧餘鏇繭淵築 (顧鬱選遞窪壓積窪鹹積, 3.045) 更多 | ||||||
临床2期 | 37 | 築範淵糧鏇糧積鹽壓壓 = 鏇糧構製構齋鬱積鬱鏇 觸鹽襯構鏇鬱鏇鏇淵繭 (獵網醖構壓餘艱膚選願, 糧鹹淵鑰遞壓膚餘繭鏇 ~ 衊網網窪願顧襯壓遞蓋) 更多 | - | 2020-12-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用